INTRODUCTION {#s1}
============

Seasonal human influenza A virus (IAV) annually hospitalizes millions of people and kills hundreds of thousands ([@B1]). IAV remains endemic despite high levels of adaptive immunity in nearly all humans after early childhood. IAV persists due to selection of mutants with amino acid substitutions in the viral hemagglutinin (HA) glycoprotein that enable escape from neutralizing antibodies allowing periodic reinfection of adults with the same subtype. HA is a homotrimeric glycoprotein with a globular head domain resting atop a stem that anchors HA to the virion surface. The head has a receptor binding site that attaches virions to cell surface terminal sialic acid residues, initiating infection. Ab binding to the head neutralizes virus by blocking attachment. Understanding Ab-driven HA evolution is essential to improving influenza vaccination, which currently offers only moderate protection from infection ([@B2], [@B3]).

As newly synthesized HA enters the endoplasmic reticulum of IAV-infected cells, oligosaccharides are often, but not always, attached to asparagine (Asn; N) residues present in the motif Asn-X-serine/threonine-Y, where X and Y represent any other amino acid except proline. Attached glycans can be high-mannose glycans or larger, more complex branched glycans ([@B4], [@B5]). HAs possess multiple highly conserved glycans on the stem domain crucial for HA folding and oligomerization ([@B6]). In birds, HA heads typically remain minimally glycosylated; it has been carefully noted that evolving HAs in humans, by contrast, accumulate over time ([@B7][@B8][@B9]) and occasionally swap head glycosylation sites ([@B8], [@B10], [@B11]).

Head glycans are known to promote viral fitness by shielding virus from antibody binding and by tuning receptor affinity and specificity ([@B12][@B13][@B15]). The importance of glycan-mediated shielding was highlighted recently by a study that revealed the inability of ferrets and humans exposed to an otherwise well-matched, current H3N2 vaccine strain lacking the most recently added glycan to produce antibodies that robustly neutralized glycosylated virus ([@B16]). Despite their clear role in antibody evasion, glycan changes are generally not correlated with changes between antigenic clusters ([@B17]).

This is the case in part because glycan addition typically lowers HA receptor avidity ([@B18]), complicating binary assays such as those evaluating hemagglutination inhibition (HI) ([@B19]). Further, antigenic clusters are defined by HI assays performed using ferret antisera, but HA head glycans are selected to escape neutralization by human antibodies specific for antigenic sites that, typically, are weakly targeted by ferret antibodies and that may not inhibit viral attachment ([@B20]). Consequently, despite glycan evolution being a major contributor to antigenic escape, it is often left unaccounted for in studies using HI-based analytic tools such as antigenic cartography ([@B21], [@B22]).

Despite selective advantages offered by antigenic shielding, glycan addition can also exact a high fitness cost for viruses by deleteriously altering receptor binding, enhancing viral neutralization by innate immune lectins, or increasing stress in the endoplasmic reticulum during translation ([@B19], [@B23][@B24][@B27]).

RESULTS {#s2}
=======

Empirical analysis of relative HA sizes over time. {#s2.1}
--------------------------------------------------

Studies of HA glycan evolution rely nearly exclusively on bioinformatic predictions of glycan addition. NetNGlyc ([@B28]) predicts N-linked glycosylation ([@B5]), and servers such as GlyProt can be used to filter out sites by considering structural constraints such as surface accessibility, but neither provides either a guarantee that glycans were added or information regarding added glycan structure. We therefore used gel electrophoresis to monitor glycan addition to HAs from 72 egg-grown H1N1 and H3N2 strains as determined by decreased HA migration ([Fig. 1](#fig1){ref-type="fig"}; see also [Fig. S1](#figS1){ref-type="supplementary-material"} to [S3](#figS3){ref-type="supplementary-material"} and [Table S1](#tabS1){ref-type="supplementary-material"} in the supplemental material and File S1 \[<http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>\]).

![Quantitative survey of HA glycan numbers in IAV. (A) Relative HA sizes, measured by migration rate through a gel, correlate with predicted numbers of head glycans. H1N1s (triangles) add 3.3 ± 0.2 kDa per glycan (or 13.1 kDa in total) while increasing from 1 to 5 glycans. H3N2s (HA1; circles) add 2.5 ± 0.2 kDa per glycan (or 12.5 kDa in total) while increasing from 2 to 7 glycans. Each point represents the mean HA size for one virus. Error bars represent standard deviations of the means. (B) HA sizes over time for H1N1s (triangles) and H3N2s (HA1; circles) reveal regular glycan addition. Glycan outliers and strains not included in analysis (open triangles) are addressed in Materials and Methods. Strains are color-coded to match glycan numbers ([Fig. S3](#figS3){ref-type="supplementary-material"}). A glycan is added on average every 5.4 years for sH1N1 and every 8.1 years for H3N2. The strain most closely related to the sH1N1 virus reintroduced in 1977, A/Fort Leonard Wood/1951, is boxed and labeled in blue. The pH1N1 strain, A/California/07/2009, is boxed and labeled in black. Data representing the Pearson coefficient of correlation (r) and its *P* value are shown on both graphs. Error bars represent standard errors of the means of data from *n* = 3 to 5 blots.](mBio.00204-19-f0001){#fig1}
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SDS-PAGE analysis of purified virus. Molecular weight standards are labeled. Representative blots are shown. Lane identifications with reassortant status are shown below the blots. The source of the strain, the yield, and the hemagglutinin units are shown for each lane in File S1 (<http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>). Download FIG S1, TIF file, 2.2 MB.
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List of H3N2 glycan outliers, indicating changes in glycan numbers and kilodaltons. Download Table S1, PDF file, 0.05 MB.
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Growing all viruses in eggs ensured a standardized viral output. Our choice of assay is associated with several potential experimental artifacts; namely, glycosylation patterns can differ between species, and egg adaptation of human viruses can lead to mutations in HA. Further, amino acid differences between HAs could also affect electrophoretic shift independently of glycosylation. PNGase treatment of viruses indicated that this effect was minimal compared to glycosylation-mediated size changes ([Fig. S2D](#figS2){ref-type="supplementary-material"} and [E](#figS2){ref-type="supplementary-material"}). Despite the potentially confounding influence of our experimental choice, with the large sample size, we found that HA migration strongly correlated with the number of computationally predicted head glycosylation sites ([Fig. 1A](#fig1){ref-type="fig"}). H1 adds an apparent 3.3 ± 0.2 kDa (*R*^2^ = 0.93) per glycan, suggesting that the majority of such glycans are highly branched. The average H3 glycan, by contrast, is smaller (2.5 ± 0.2 kDa, *R*^2^ = 0.44), consistent with greater levels of addition of simpler glycans. The size difference between H1 and H3 HA glycans is consistent with mass spectrometry characterizations showing that H1 glycans skew to larger, more complex structures whereas the majority of H3 glycans at several sites are high-mannose glycans ([@B5], [@B12]).
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Identification of viral proteins in Coomassie blue-stained gels. (A) Purified whole PR8 or reassortant, detergent split viruses were stained with Coomassie blue and probed with monoclonal antibodies against HA1 (CM1), NA N1 (C-terminal), and HA2 (RA 5-22) or against convalescent sera from a H3N2 reassortant-infected mouse. (B) H3N2 HA monomer and H3N2-HA1 band sizes correlate almost perfectly. As the resolution was better for H3N2-HA1, these were used for analysis. Error bars represent standard errors of the means of data from *n* = 3 to 5 blots. (C) (Left) Representative Western blots of NP and M1 proteins, which served as an internal ruler. (Right) Quantitation of relative sizes of NP and M1. Raw data (gray) were normalized to account for gel distortion (open black symbols). The average size of each protein is shown on the *y* axis. Error bars represent standard errors of the means of data from *n* = 3 to 5 blots. (D) PNGase-treated viruses. (Left) Western blots (HA, red; NA, green) and Commassie blots (gray) for strains A/Melbourne/1/1946 (strain 8) and A/USSR/90/1977 (strain 15) with and without PNGase treatment. (Right) HA1 *M~r~* measurement from Western blot for strain 8, strain 15, and strain 26 (A/Brisbane/59/2007). (E) (Top) Coomassie blot reproduced from [Fig. S1](#figS1){ref-type="supplementary-material"}, showing non-PNGase-treated HA. (Middle) Similar Coomassie blot showing PNGase-treated viruses. The major band is shown overlapping HA1/NP, which run at similar sizes. (Bottom) Western blot of PNGase-treated viruses stained for HA. Download FIG S2, TIF file, 2.3 MB.
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IAV viral panel. (A and B) H1N1 viruses (A) or H3N2 viruses (B) with the predicted glycosylation status of HA Asn (N^+^ or N^−^), the substituted residue present, or a deletion (Del). The total number of head glycans, relative HA sizes represented as migration rates through the gel (*M~r~*), and year of virus collection are shown for each virus. Glycans conserved among all viruses are listed below each table. Download FIG S3, TIF file, 2.3 MB.
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Importantly, the total numbers of glycans and glycan mass added to the head during antigenic drift in humans are similar between subtypes: H1 added 4 glycans, or 13.1 kDa, for a maximum of ∼16.5 kDa of glycans per monomer, and H3 added 5 glycans, or 12.5 kDa, for a maximum of ∼17.5 kDa of glycans per monomer. These values are consistent with the idea of an upper limit of glycan shielding for H1 and H3 HA head domains, although it remains to be seen which specific features of glycosylation, such as number, mass, or type, are important for determining this limit.

H1 HA glycan evolution. {#s2.2}
-----------------------

Plotting relative HA size versus time reveals the history of seasonal H1N1 (sH1N1) glycosylation ([Fig. 1B](#fig1){ref-type="fig"}, triangles). First-wave sH1N1 (1933--1957) HAs behaved differently from the second-wave sH1N1 representatives (1977--2008). During the first wave, relative HA size increased by an average of 3.3 kDa, or one glycan, every 5.4 years (slope = 0.61 kDa/year, *R*^2^ = 0.86).

As expected, the sH1N1 strains that reemerged after the 1977 reintroduction of sH1N1 exhibited relative HA sizes similar to those of the most related strain, A/Fort Leonard Wood/1951 (inside blue box, [Fig. 1B](#fig1){ref-type="fig"}). Rather than increasing in number as had occurred previously, electrophoresis confirmed the NetNGlyc prediction that these 5 HA-head glycan strains were maintained until they decreased to 4 glycans after 1991.

Indeed, HA sequences predicted to have 6 head glycans were highly unusual over the century of H1 evolution (1918 to 2017), except in 1986 and 1987, when they accounted for \>50% of H1 strains ([Fig. S4A](#figS4){ref-type="supplementary-material"}, black). Rather than adding glycans, sH1N1 strains that reemerged after 1977 exhibited glycan adjustments spaced at longer intervals of 10.3 ± 0.8 years ([Fig. 2](#fig2){ref-type="fig"}). In 1986, N54 pandemic H1N1 (pH1N1) (the numbering convention is shown in [Table S1](#tabS1){ref-type="supplementary-material"}) replaced N155, as N127 swapped with N125. Around 1997, N269 was lost. Strains with the 4 remaining glycans circulated for 11 years before becoming extinct during the 2009 pH1N1 pandemic. During at least 33/35 seasons after the glycan limit was reached, sH1N1 failed to evolve a widely circulating strain with 6 glycans. This history is consistent with a functional glycan limit.

![H1 glycan evolution, 1918 to 2017. (A) Stacked bars correspond to the percentages of all human H1N1 sequences from a given year containing a glycan listed in the legend. Dates of glycan transition are indicated on the timeline at the bottom, along with the glycosylated residues. Years with no data were left blank. Sequence counts for each year are shown in [Fig. S4A](#figS4){ref-type="supplementary-material"}. Pandemics are denoted by yellow lines. (B) Mean predicted numbers of glycans among all sequences from each year are shown as black circles, which are displayed atop the idealized pattern (gray line; the light blue line indicates glycan swap from sequences containing N127/N155 to sequences containing N125/N54). Black vertical lines denote 11-year intervals after the glycan limit was reached or 6-year intervals during glycan addition. Data representing Pearson's coefficient of correlation (r) with sample number (n) and *P* value, from two-tailed Student\'s *t* test comparing the pattern versus the sequence data are shown at the bottom.](mBio.00204-19-f0002){#fig2}
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Frequency of total sequences according to the number of glycosylation sites. (A and B) Percentages of H1N1 (A) or H3N2 (B) sequences in FluDB, with numbers of predicted head glycans indicated. Above each lane are shown the total numbers of sequences in FluDB from the indictated year. *y*-axis data are presented in logit scale. Sequences above the functional limits of 6 glycans for H1N1 and 8 glycans for H3N2 are shown in black. Download FIG S4, TIF file, 1.1 MB.
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H2 HA glycan evolution. {#s2.3}
-----------------------

Despite being experimentally possible, during their 11-year era (1957 to 1967), human H2N2 never added or swapped any glycans.

The H2N2 HA head has two highly conserved overlapping glycans with the sequence NNTS, where either, but not both of the Asns can be glycosylated ([@B29]). While it remains unknown which Asn (or which mixture) is glycosylated in H2 HA, the kinetics of NXT glycosylation are faster than the kinetics of NXS glycosylation ([@B30]) and overlapping sites in yeast, mice, pH1N1, and H5N1 prefer NXT to NXS ([@B31][@B32][@B34]).

Selection of H2N2 strains with additional head glycans outside the overlapping site occurs readily during *in vitro* antibody escape. These multiglycan H2 HAs, however, exhibit drastically lower levels of cell fusion and receptor binding ([@B29]).

H3 HA glycan evolution. {#s2.4}
-----------------------

As with H1 HAs, H3 HAs exhibit regular intervals of glycan evolution, with one exception ([Fig. 3](#fig3){ref-type="fig"}). The original (1968) pandemic H3 strains had 2 head glycans. Four times since 1968, glycans were added to H3 HA at regular intervals of 5 to 7 years (N126 by 1974, N246/N122 by 1980, N133-plus-N122 replacement of N276 by 1998, and N144 by 2004) ([Fig. 4](#fig4){ref-type="fig"}). This timing is similar to that corresponding to the average rate of glycan addition (one glycan every 5.4 years) seen by SDS-PAGE for sH1N1 from 1933 to 1951.

![H3 glycan evolution, 1968 to 2017. (A) Stacked bars correspond to the percentages of all human H3N2 sequences from a given year containing a glycan listed in the legend. Dates of glycan transition are indicated on the timeline at the bottom along with the glycosylated residues. Sequence counts for each year are shown in [Fig. S4B](#figS4){ref-type="supplementary-material"}. Mean predicted numbers of glycans among all sequences from each year are shown as black circles, which are displayed atop the idealized pattern (gray line; the red line indicates glycan transition from sequences containing N144 to sequences containing N158). The dashed gray line indicates when N276 would have been added if it had followed the pattern. Black vertical lines denote 11-year intervals after glycan limit was reached or 6-year intervals during glycan addition. Data representing Pearson's coefficient of correlation (r) with sample number (n) and *P* value from two-tailed Student\'s *t* test comparing the pattern versus the sequence data are shown at the bottom.](mBio.00204-19-f0003){#fig3}

![Quantitative analysis of glycan eras. (A) The duration (in years) of each glycan era corresponds to the interval when \>10%, \>50%, or \>80% of sequences had the new glycan arrangement. The data shown for the duration of the glycan era correspond to the range of these three dates. (B) The durations of glycan eras ended by glycan addition were, on average, half as long as those seen after the glycan limit was reached (Student's two-tailed *t* test, *P = *0.0079). Eras ended by pandemic replacement are denoted by open circles.](mBio.00204-19-f0004){#fig4}

With the addition of the 7th head glycan in 2004, H3 HA had increased in size by 12.5 kDa from the original 1968 strain. We hypothesize that H3N2 reached the functional glycan limit at this point ([Fig. 3B](#fig3){ref-type="fig"}). It is apparent from sequence data that H3 HAs with \>7 head glycans lose the competition for human circulation. While 8-glycan strains circulate, they represent \<1% of H3N2 sequences in any year ([Fig. S4B](#figS4){ref-type="supplementary-material"}). Similarly to the second-wave H1 viruses, 12 to 15 years after reaching the glycan limit, a glycan swap occurred, as the glycan at residue N144 was lost and a new residue at N158 was gained ([Fig. 3B](#fig3){ref-type="fig"}; see also [Fig. S5B](#figS5){ref-type="supplementary-material"}).
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\(A\) Major pH1N1 clades track with glycosite evolution. (Top) Recent pH1N1 phylogeny. (Bottom) Frequencies of sequences in each clade. Clade 6 is shown in black, clade 6b1 in light gray, and clade 6b1.A in dark gray. Red slashes on phylogeny denote the glycosite mutations indicated in red at the bottom. Vaccination strains are marked with an X. Since 2013, the following 4 additional HA mutations have been fixed: S84N and signal peptide A13T in 2013 and S74R and I295V in 2016. (B) H3N2 HA glycans are currently undergoing selection. Following selection for 3c2.A (light gray), several clades (A1 to A4 \[colored in phylogenetic tree at the top\]) have begun to circulate simultaneously. Two of these clades, A1b/135K (dark gray) and Ab1/135N (black), have mutations that alter the predicted glycosylation of N133. Sequence frequencies and predicted glycosylation changes averaged over 2018 are shown in the inset. Vaccination strains are marked with an X. The figure was produced using nextstrain.org (previously nextflu) ([@B53], [@B54]). Download FIG S5, TIF file, 1.2 MB.
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There was one exception in the 5-to-7-year-interval pattern for H3 glycan addition. Addition of a fifth glycan, at residue 276, occurred 12 to 13 years after the previous glycan addition ([Fig. 3A](#fig3){ref-type="fig"}, orange). In 1993, robust strains with N276 swept the globe, dominating sH1N1 strains, before disappearing. N276 is unique as the glycan-bearing Asn residue is immediately adjacent to a structurally important disulfide-bonded cysteine (C275) which defines the HA head-stem border.

pH1 HA follows the sH1 glycosylation pattern. {#s2.5}
---------------------------------------------

The initial 2009 pH1N1 strains had a single predicted head glycan (N87). As expected, the HA of a representative early strain, A/California/07/2009 ([Fig. 1B](#fig1){ref-type="fig"}, inside black box), comigrated with strains from the 1930s and with two other swine-origin human strains, A/New Jersey/8/1976 and A/Memphis/4/1982, with a single predicted head glycan ([Fig. 1B](#fig1){ref-type="fig"}, red triangles). From SDS-PAGE, we calculated that seasonal H1N1 added a glycan every 5.4 years before reaching the glycan limit. If pH1N1 were to follow the same trajectory, we predicted that it would add a glycan over the 2015 to 2016 season. Analysis of sequences from this period revealed that, indeed, a second glycan site arose through an S-to-N change at residue 162 over the 2015--2016 season ([Fig. 5A](#fig5){ref-type="fig"} and [B](#fig5){ref-type="fig"}).

![pH1N1 glycan addition predicted from gel migration data. (A) Frequency of human pH1N1 sequences in FluDB determined by the number of predicted glycans in each calendar year. The number of sequences represented by each bar is shown above the bar. Until January 2015, \>90% of sequences had 1 glycan (black). Starting in 2015, strains with 2 glycans swept the globe (red). (B) Frequency of individual residues glycosylated in human pH1N1 sequences. N87 predominates throughout (\>95%, black). N162 (red) and N136 (blue) appeared at low frequencies until 2015, when strains having both N162 and N87 dominated. N162 strains were found in every year. Rarely, in addition to N87, a residue other than N162 or N136 was found to have a potential glycosylation site (gray). Unlike N162, a single mutation with N136 alone is sufficient for glycosylation ([@B14]). (C) HA Western blots of A/California/07/2009 mutants with permutations of N162, K163Q, and I216T with and without PNGase treatment to remove glycans. The single mutant with N162 alone did not shift in size, indicating that it was not detectably glycosylated. While a portion of the double mutant N162/K163Q shifted, a complete shift, indicating majority glycosylation, was seen only with the triple mutant N162/K163Q/I216T.](mBio.00204-19-f0005){#fig5}

Two changes are necessary for complete glycosylation of N162. {#s2.6}
-------------------------------------------------------------

N162 viruses were present at low frequencies in each season since pH1N1 introduction ([Fig. 5A](#fig5){ref-type="fig"} and [B](#fig5){ref-type="fig"}). Viruses with this mutation did not selectively sweep the human pH1N1 strains until the 2015--2016 season ([Fig. 5](#fig5){ref-type="fig"}; see also [Fig. S5A](#figS5){ref-type="supplementary-material"}). All of these strains, unlike previous N162 strains, also had an I216T mutation.

Residue 162 is in an antigenic site ("Sa") ([@B35]) that is immunodominant in many contemporary human Ab responses ([@B36]). Prior to the N162 glycan sweep during the 2013--2014 season, pH1N1 was swept aside by strains that were antigenically distinct due to a K163Q mutation co-occurring with an A256T mutation ([@B36], [@B37]). Surprisingly, through reverse-genetics manipulation of the A/California/07/2009 strain, we found that, despite their having the amino acid sequence necessary for glycosylation, neither the N162 single mutants nor the N162/K163Q double mutants added a glycan to HA in virions. Rather, three mutations, namely, N162 itself, K163Q, and, crucially, I216T, were required for complete glycosylation of the 162 site ([Fig. 5C](#fig5){ref-type="fig"}).

Interestingly, in H3 strains that also possess a N162 glycan, the residue equivalent to residue 216 in pH1N1 is also a small polar amino acid, serine, suggesting strong epistasis between S and T at position 216 and glycosylation at position 162. This is puzzling, since as a cotranslational process, N-linked glycosylation should not be controlled by a residue 54 positions downstream from the glycosylation site ([@B38]). Could it be that residue 216 influences the fitness of residue 162 glycosylation at the level of trimer structure/function? To calculate approximate distances between the residue 162 glycan and the 216 residue, we created a homology model of A/Michigan/45/2015 HA with a likely triantennary glycan at N162 ([Fig. 6](#fig6){ref-type="fig"}). The model shows that the side chain of 216 is highly exposed and faces the glycan, consistent with an epistatic interaction. It must be added, however, that in a static model, the distance of ∼9 Å between the position 162 glycan and residue 216 is inconsistent with steric or polar interactions with T216 (\<3.5Å). Possible explanations include the following: (i) the attached oligosaccharide is larger than the glycan modeled; (ii) the conformational breathing of the HA brings the glycan into proximity to residue 216; and (iii) residue 216 epistatically interacts with the glycan (or with glycosylation itself) on the monomer rather than on the trimer.

![HA model highlighting key HA residues. Complete A/Michigan/45/2015 HA with an attached N162 glycan, embedded in a lipid bilayer, is shown from the side (left) and top (right). Three residues defining the N162 glycosite have undergone recent mutations, and their surfaces are shown in pink as follows: S162N, 2016--2017; K163Q, 2013--2014; and S164T, 2017--2018. The original I216 mutation (cyan) the and compensatory T216 mutation (magenta) stick side chains are overlaid across the monomer from the glycan. The surface of a slightly earlier antigenic site mutation, S84N, is indicated in green. All additional glycosylated Asn residues on HA are shown in pink. The inset shows a magnified view of the mutated residues with ∼9 Å of distance between the Thr hydroxyl group and the nearest GlcNAc hydroxyl group.](mBio.00204-19-f0006){#fig6}

Phylogeographic reconstruction of glycan sweep. {#s2.7}
-----------------------------------------------

A phylogenetic analysis of all HA sequences from pH1N1 viruses collected globally during 2009 to 2017 revealed that N162/I216T viruses emerged repeatedly during 2009 to 2014, particularly in North America and Europe ([Fig. 7A](#fig7){ref-type="fig"}, blue spikes), but did not predominate and were quickly replaced by other strains ([Fig. 7A](#fig7){ref-type="fig"}; see also File S12 and S13 at <http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>). Previous studies have identified 2014 as a turning point in pH1N1 evolution, when the pH1 phylogeny became more ladder-like, with a single dominant lineage, presumably owing to a high proportion of the global population being exposed to pH1N1 by that time ([@B11]).

![Global emergence of N162/I216T strains. (A) Proportions of all globally available H1 sequences from pH1N1 viruses collected in 2009 to 2017 from the GIASAID database with the N162/I216T substitutions are indicated for 12 geographical regions over time (in Africa, Egypt, Cameroon, and Ethiopia; in Central America, Costa Rica; in Central Asia, Kazakhstan and Kyrgyzstan; in East Asia, Japan, China, Hong Kong, Taiwan, and South Korea; in Europe, Iceland, Austria, Netherlands, Germany, Russia, Denmark, Norway, United Kingdom, Ukraine, Greece, Sweden, and Belgium; in the Middle East, Iran, Oman, Bahrain, Jordan, Turkey, Afghanistan, and Israel; in North America, the United States and Canada; in Oceania, Australia; in the Pacific Islands, Hawaii; in South America, Brazil; in South Asia, India, Nepal, Bangladesh, and Pakistan; and in Southeast Asia, Singapore, Philippines, and Cambodia). The 95% HPD intervals for mean time to the most recent common ancestor (tMRCA) are indicated by vertical blue or gray shadows. (B) The posterior probability support for the geographical origin of the major clade of N162/I216T and S84N viruses is indicated by the shade of the country (light blue = low posterior probability, dark blue = high posterior probability), inferred from the MCC tree. This figure is reproduced with separated proportions of sequences panels in File S11 (<http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>).](mBio.00204-19-f0007){#fig7}

Our findings are consistent with this observed timing of immune-driven selection, as the N162/I216T strains rapidly swept to dominance globally beginning in late 2014 and represented 100% of pH1N1 viruses in most regions by 2017. The sharp rise of N162/I216T strains to dominance during 2015 occurred simultaneously in multiple regions ([Fig. 7A](#fig7){ref-type="fig"}; see also [Fig. S6A](#figS6){ref-type="supplementary-material"}), making it difficult to infer the most likely spatial origin of these strains and resulting in low posterior probabilities for all regions ([Fig. 7B](#fig7){ref-type="fig"}). In contrast, the geographical origins of the S84N substitution is strongly supported in South Asia, where S84N strains gradually increased in frequency during 2013 to 2015 before becoming dominant in other regions ([Fig. 7](#fig7){ref-type="fig"}; see also [Fig. S6B](#figS6){ref-type="supplementary-material"} and [Fig. S7A](#figS7){ref-type="supplementary-material"}), providing a distinct spatial pattern for the phylogeny and high posterior probabilities (0.74 in South Asia). Similarly to N162/I216T, the S84N substitution also was present in pH1N1 viruses during earlier years of the pandemic but also died out quickly ([Fig. 7A](#fig7){ref-type="fig"}, gray spikes).

10.1128/mBio.00204-19.6

Maximum likelihood trees of strains with (A) S84N and (B) N162/I216T colored by region. Posterior probability data are shown for the node defining the S84N and N162/I216T dominant clades. Download FIG S6, TIF file, 1.5 MB.
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\(A\) Numbers of seasonal influenza cases from 2009 to 2015, retrieved using the World Health Organization FluNet tool ([@B55]). (B) (Top) Numbers of sequences per region for S84N within the first year and a half of detection (291 sequences). (Bottom) Sequences from N162/I216T obtained within its first year of detection (556 sequences). (C) (Top) Number of samples per region after subsampling for S84N (125 sequences). (Bottom) Number of samples per region after subsampling for N162/I216T (159 sequences). Download FIG S7, TIF file, 1.0 MB.
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DISCUSSION {#s3}
==========

Through empirical analysis of HA glycosylation, we revealed regular patterns of glycan evolution that have followed decades-long trajectories. Initially, a strain from the animal IAV reservoir with minimally glycosylated HA establishes worldwide circulation in humans. At regular 5-to-7-year intervals, head glycans are added to HA. After a functional glycan limit is reached, head glycans are swapped at longer intervals until pandemic replacement occurs ([Fig. 4](#fig4){ref-type="fig"}). Glycan changes have occurred with discrete, globally rapid, selective sweeps of IAV, as well as with slower increases over multiple seasons (see [Fig. S5](#figS5){ref-type="supplementary-material"} in the supplemental material).

Several issues surrounding this pattern will require further study. For instance, if the major role of glycosylation is to shield antigenic sites, loss or swapping of a glycan would presumably open a previously covered antigenic region against which older individuals might be protected. Determining the impacts of glycan addition versus glycan loss or swap will be important. Considering both H1 and H3 HA glycan evolution, glycan loss occurred in all 3 glycan changes after their glycan limits were reached (for H1N1, loss of N127 and N155 around 1987 and loss of N269 around 1997; for H3N2, loss of N144 around 2014).

The pattern described in this paper derives from 13 glycosylation changes and 3 subtype extinctions over the past 100 years. As these events are rare, the data set is limited and even within the limited data, the pattern contains inconsistencies. The biggest of these inconsistencies is the addition of N276 to H3N2 in 1992 to 1993 after 12 to 13 years rather than 5 to 7 years. In the HIV env glycoprotein, glycans are enriched at the C-terminal residues of disulfide bonds, but absent from residues on the N-terminal side. We speculate the N-terminal glycan at N276, adjacent to C277, may have reduced the fitness of these strains and their competitiveness against future strains lacking N276 ([@B57]).

These and other concerns leave open the issue of whether IAV will maintain the patterns outlined here in the near future. For instance, will pH1N1 rapidly add a third glycan in the next few years? Will H3N2 once more swap (or lose) glycans or will it go extinct in the next decade? Or, instead, will it surpass our proposed glycan limit by adding an eighth glycan?

What is clear is that glycosylation sites in both pH1N1 and H3N2 are under intense selective pressure. For instance, pH1N1 HA mutation S164T swept the globe over 2017 to 2018, altering the N162 glycosite motif from NXT to NXS ([Fig. S5A](#figS5){ref-type="supplementary-material"}). The kinetics of NXT glycosylation are known to be faster than those of NXS glycosylation, suggesting that this mutation could facilitate glycosylation at N162. This also means that between 2013 and 2018, all three residues composing the N162 glycosylation site had mutated (SKS to NQT). For H3N2, two new clades have recently begun to circulate with either a T135K or T135N mutation. Both mutations remove the glycan at N133; however, the T135N mutation also creates a new glycosylation site at N135 ([Fig. S5B](#figS5){ref-type="supplementary-material"}). With either 6 or 7 glycans, these strains remain under the glycan limit.

Experimentally, it has been shown that H1 HAs can accommodate at least 8 head glycans while maintaining *in vitro* fitness ([@B39]). However, sH1 circulated for over 3 decades after reaching 5 glycans without fixation of a sixth glycan. Interestingly, at 9 to 10 years after reintroduction in 1977, sH1N1 strains with 6 glycans did briefly circulate before being replaced by strains with only 4 glycans. These findings point to *in vivo* glycan-based fitness costs involved in maintaining the glycan limit, possibly due to structural constraints on the HA protein, innate immune mechanisms, or alterations in virus binding to receptors found in human airways ([@B40]). However, if the pattern does indeed hold up over time, it requires explanation. We propose a simple albeit provocative rationale to account for this observation.

Every IAV season, swarms of closely related minor variants sample broad swaths of mutational space ([@B41]), including new glycan sites. In large, age-stratified populations, this constant sampling allows circulating strains to seasonally detect and quickly respond to changes in the immune context. In an antigenically naive population, an HA head with *n* glycans is fitter than an HA head with *n* + 1 glycans. As Ab pressure mounts, the fitness costs associated with adding a glycan are outweighed by the advantage conferred by antigenic shielding. We propose that a period of 5 to 7 years is required to provide sufficient herd immunity to enable the dominance of glycan addition mutants.

We also note that the average period of time during which a glycan addition has become dominant in human H1 or H3 strains is strikingly similar to the 5.3-year average for the emergence of norovirus genotype GII.4 variants over the past 30 years ([@B42]). While glycan evolution is not involved in creating antigenically distinct GII.4 norovirus variants, the similar kinetics of these two globally drifting viruses may reflect broad similarities in the rates at which global humoral immunity builds to enable selection of escape mutants with higher fitness costs.

On the basis of our work, using biochemistry, immunology, and phylogenetics, we can attempt to reconstruct the 2016 selection of the N162 glycan addition. Antibody pressure on the Sa antigenic site first selected for the K163Q escape mutation, which replaced other pH1N1 strains. Several years of immune pressure against this new Sa site led to co-selection of the N162 glycan and I216T, which increases N162 glycosylation.

In humans, the HA head of both the H1 and H3 subtypes contains 5 or so potentially immunodominant, mutationally plastic, largely antigenically independent epitopes. Evolution among these epitopes over decades facilitates repeated infection of adults with the same IAV subtype. The HA head's antigenic dominance ([@B43]), in combination with the glycosylation patterns outlined in this paper, has conferred a fitness advantage for long-term IAV persistence in large, age-stratified populations whose members are reliant on anti-HA head antibody-mediated IAV immunity, i.e., humans. The patterns in glycan evolution that we have observed likely increase viral fitness by subverting antibody-based immunity over decades-long time scales in these populations. Taken together, the data indicate that H1 and H3 HAs may be adapted for optimized antigenic drift or, put a different way, that HA has evolved to drift. If true, similarities among sH1, pH1, and H3 glycan changes highlight the possibility that rough blueprints for the pattern that we observe are potentially stored in the fitness landscape of the HA protein itself.

MATERIALS AND METHODS {#s4}
=====================

Virus preparation and purification. {#s4.1}
-----------------------------------

We propagated each virus by infecting five 10-day-old embryonated chicken eggs with 100 μl of viral stock diluted 1:2,000 in phosphate-buffered saline (PBS). Infected eggs were incubated at 34.5˚C and 65% humidity for ∼41 h. We first clarified the allantoic fluid (AF) by centrifugation at 4,500 × *g* for 20 min and then pelleted the virus by centrifugation for 2 h at 26,000 × *g*. After incubating the viral pellet in 1.7 ml PBS overnight at 4˚C, we layered the virus onto a discontinuous 15%-to-60% sucrose gradient and spun it at 34,000 × *g* for 2 h. We collected virus at the gradient interface and spun it a final time in PBS at 34,000 × *g* for 2 h. Virus was resuspended in 100 μl PBS and stored as milky opalescent suspensions in long-term storage at 4˚C. Hemagglutination titers for each virus were measured from neat AF. A complete list of viruses and their origin is available in File S1 at <http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>. The total protein content of each virus preparation was determined by a Coomassie blue-based assay performed per the instructions of the manufacturer (Bio-Rad; DC assay).

AF from eggs infected with 72 of the 75 viruses that we attempted to grow showed hemagglutination activity (HAU), indicating viral presence. We collected pure virus from all virus preparations in amounts ranging from 20 to 6,920 μg. Sham infection and purification of AF from control eggs did not produce enough protein for detection, and the preparation ran cleanly on a gel (10 μl of a 100-μl preparation) (see lane 29 in [Fig. S1](#figS1){ref-type="supplementary-material"} in the supplemental material).

To determine the identity of individual bands on the Coomassie gel, we grew H1N1/H3N2 reassortant viruses A/HK/68 (HK), A/PR8/MCa (PR8), X31 (HK HA and neuraminidase \[NA\], PR8 background), J1 (HK HA, PR8 background), and P50 (PR8 HA, HK background). These viruses were run together on the same gel and immunoblotted with appropriate antibodies to determine which bands corresponded to which proteins via Coomassie blue staining ([Fig. S2A](#figS2){ref-type="supplementary-material"} and [B](#figS2){ref-type="supplementary-material"}). We used the following antibodies: mouse anti-HA1 monoclonal antibody (mAb) (CM1); mouse anti-HA2 mAb RA 5-22; anti-M1 (M2-1C6; anti-mouse antibody recognizing 9-kDa N-terminal fragment); anti-NP C-terminal rabbit polyclonal antibody 2364 (487 to 498); anti-NP HB-65; anti-NA C-terminal anti-rabbit polyclonal antibody.

To determine the effect of S162N, K163Q, and I216T mutations on glycosylation of pH1N1 HA, we made HA plasmids with different mutation combinations in the A/California/07/2009 HA background, which also included an additional D222G mutation to increase yield in eggs ([Fig. 5C](#fig5){ref-type="fig"}). Reassortant viruses with mutant HA and NA from A/California/07/2009 and internal segments from PR8 were rescued and grown in eggs. Virus was enriched from AF by centrifugation, standardized by enzyme-linked immunosorbent assay (ELISA) using a stem-reactive antibody (C179), and visualized by SDS-PAGE using the anti-HA CM-1 antibody. A portion of each virus was treated with PNGase F.

Protein gels and immunoblotting. {#s4.2}
--------------------------------

We mixed purified virus (1 μg protein) with 4× NuPage loading buffer (Invitrogen) and boiled the mixture for 10 min at 96˚C. We electrophoresed samples with a Chameleon Duo Li-Cor ladder on 4% to 12% Bis-Tris gels (Invitrogen) at 200 V for 55 min. To visualize proteins, we fixed gels for 10 min with 10 ml 10% acetic acid and 50% methanol (with shaking) at room temperature (RT). After removal of the fixative, we added 10 ml GelCode stain (Pierce), shook the resulting preparation for 30 min at RT, and then destained the gels with water overnight. For immunoblotting, we transferred proteins from gels to polyvinylidene difluoride (PVDF) membranes with an iBLOT system at the P3 setting for 7 min. We blocked membranes for 30 min at RT using StartingBlock blocking buffer (Thermo Scientific). After incubation with primary antibody or sera for 1 h at RT and five washed performed for 5 min each wash in TBST (10 mM Tris, 150 mM NaCl, 0.1% Tween 20), we added secondary antibody, repeating the washing step for the incubation.

We imaged blots and Coomassie gels on a Li-Cor Odyssey system. Band signals and molecular weights were calculated using ImageStudio software (Li-Cor). Glycoprotein molecular weights were normalized for gel distortion, commonly called "smiling," by adjusting each glycoprotein molecular weight by the average amount that the M1 and NP molecular weight for each virus differed from the mean molecular weight of M1 and NP proteins on each gel ([Fig. S2C](#figS2){ref-type="supplementary-material"}). Amino acid mutations in HA can shift the electrophoretic mobility of HA regardless of the presence or absence of glycan attachment. After PNGase treatment of the viruses, the electrophoretic shift caused by the amino acid mutations was minimal in our assay compared to the larger glycan shifts ([Fig. S2D](#figS2){ref-type="supplementary-material"} and [E](#figS2){ref-type="supplementary-material"}). On the basis of this finding, and to avoid overcorrection, we chose to calculate mobility shifts normalized only to NP and M proteins within the same blot. Linear regression, Pearson coefficient, and *P* values were calculated using PRISM software.

Glycan outliers. {#s4.3}
----------------

Six data points in [Fig. 1](#fig1){ref-type="fig"} represent glycan outliers. The first, corresponding to A/Georgia/M5081/2012 (strain 28), a pH1N1 strain, is predicted to have 1 head glycan but migrated much more slowly than expected. We made a new viral stock and subjected it to deep sequencing to confirm its identity. There were no additional predicted N-linked glycans. Among those in our panel of H1N1s (which included another contemporary pH1N1 A/California/07/2009 strain, namely, strain 27), this HA alone did not immunoblot with the anti-H1 HA monoclonal CM1 antibody even though the CM-1 peptide epitope used to generate the MAb was present. We suspect that the conformation of this protein is somehow altered under SDS-PAGE conditions, changing the HA migration through the gel and altering its interaction with CM-1. These interesting and perplexing findings will be pursued in future experiments.

Four H3N2 sequences, detailed in [Table S1](#tabS1){ref-type="supplementary-material"}, have mismatched numbers of glycans compared to the other members of their clade shown in [Fig. 1](#fig1){ref-type="fig"} and [Fig. S3](#figS3){ref-type="supplementary-material"}. Strains predicted to have more glycans than other closely related strains were found to run at levels equal to or higher than those seen with other members without the additional glycan. This indicates that even though they are predicted to have more glycans, they actually appear to be less extensively glycosylated. One of these, A/Victoria/361/2011, is the only H3N2 in our panel that is predicted to have 8 head glycans. As indicated above, H3N2s with more than 7 predicted glycans are uncommon, implying constraints on H3 HA function that lead to incomplete glycosylation during biogenesis. In contrast, the single strain with fewer predicted glycans than the other members of its group is A/Nanchang/933/1995; it migrated as fast as other H3 strains with 3 glycans.

The H1N1 A/Texas/36-JY2/1991 strain has 5 predicted glycans but migrates faster than other 5-glycan H1N1s. Strain A/Texas/36-JY2/1991 is the only representative of viruses circulating between 1987 and 1997. There are 4 glycan differences between these strains and those with A/Fort Leonard Wood/1951-type glycosylation ([Fig. S3](#figS3){ref-type="supplementary-material"}). This could account for the decreased mobility, although more sequences would be needed to support this conjecture.

Finally, three strains ([Fig. 1B](#fig1){ref-type="fig"}, open triangles) were not included in calculating glycan addition over time. Strain A/Melbourne/1/1946 was removed because its HA is most closely related to those of strains circulating 10+ years earlier ([Fig. S3A](#figS3){ref-type="supplementary-material"}). Strains A/Denver/JY2/1957 and A/Malaysia/JY2/1954 were removed because they occurred after strain A/Fort Leonard Wood/1951, the strain most closely related to strains reintroduced after 1977.

Influenza sequences and N-glycosylation prediction. {#s4.4}
---------------------------------------------------

Human HA protein sequences were retrieved from the NIAID Influenza Research Database (IRD) ([@B44]) through the Web site at <http://www.fludb.org> (accessed 20 April 2017). Sequences with identical strain names were retained only if the majority of members had identical sequences. Sequences were aligned to A/California/04/2009 (H1N1) (FJ966082) with MAFFT v7.305b and were removed if indels existed in relation to the reference or if any ambiguities existed within the HA head. The amino acid numbering of sites important for this work is shown (with both H1 and H3 numbering conventions) in [Table S2](#tabS2){ref-type="supplementary-material"} in the supplemental material. Potential glycosylation sites were identified by searching for the NX\[S/T\]Y motif, where X and Y represent any amino acid other than proline, or by using NetNGlyc 1.0 artificial neural network-based prediction software ([@B28]). The glycan frequencies and counts and the sequences used for [Fig. 2](#fig2){ref-type="fig"} and [5](#fig5){ref-type="fig"} and [Fig. S4](#figS4){ref-type="supplementary-material"} can be found in Files S2 to S10 at <http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>. The stacked glycan plots ([Fig. 2A](#fig2){ref-type="fig"} and [Fig. 3A](#fig3){ref-type="fig"}) are similar to those reported in a previous publication ([@B9]). For the quantitative analysis of the SDS-PAGE data presented in [Fig. 1](#fig1){ref-type="fig"} and [Fig. S3](#figS3){ref-type="supplementary-material"}, residues with positive NetNGlyc scores were considered glycosylated ("N^+^"), and residues with only one negative mark were recorded as "N^−^." Both conditions were treated as having a glycan present. Glycan predictions recorded as N^−−^ were counted as negative.
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Relevant amino acid residues with H1 and H3 numbering using the system outlined by Burke and Smith ([@B56]) alongside H1 numbering starting from M=1. Residues associated with known antigenic epitopes are also identified. Download Table S2, PDF file, 0.04 MB.
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Determining the duration of glycan eras is complicated by the difficulties encountered in defining criteria to delineate limits representing a starting year and ending year, which were not always sharp. We chose to measure the durations of the glycan eras using three different thresholds, namely, 10%, 50%, and 80% of sequences having the new glycan arrangement.

Phylogenetic analysis of pH1N1 viruses. {#s4.5}
---------------------------------------

To investigate the evolution and global sweep of N162/I216T glycosylated viruses, all 34,029 pH1N1 viruses available in the in GISAID EpiFlu database from 2009 to 2017 were downloaded (HA segment) and annotated with country and date of collection. The data set was aligned using MAFFT v7.310 ([@B45]). Each HA sequence was annotated for the presence of the glycosylation substitution N162/I216T and the antigenic mutation S84N. In total, 8,069 HA sequences had N162, 7,725 HA sequences had N162/I216T, and 9,538 had S84N. The 4,911 sequences representing the S84N dominant clade in File S12 (<http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>) included 4,902 sequences with N84, 5 sequences with T84, 1 sequence with X84, and 1 sequence with S84, the latter likely representing reversion events. The 4,466 sequences representing the N162 dominant clade in File S13 (<http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>) included 4,441 sequences with N162. Among these, 4,413 sequences were N162/I216T, 17 sequences had N162/T216I, 4 sequences had N162/T216A, 4 sequences had N162/T216P, 2 sequences had N162/T216K, and 1 sequence had N162/T216X, the latter likely representing reversion events. We estimated the proportion of pH1N1 viruses with the S84N antigenic mutation or N162/I216T glycosylation circulating in 12 regions over time, using the R program ([@B46]). Additionally, we applied a locally weighted scatterplot smoothing (LOWESS) algorithm to better visualize the fast increase of both proportions. For these analyses, we grouped countries into the regions defined in [Table S3C](#tabS3){ref-type="supplementary-material"}.
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\(A\) Marginal-likelihood estimation for different coalescent models. (B) Date of divergence for S84N and N162/I216T using a constant population size and exponential-growth coalescent models. (C) Countries included per region for each analysis. Download Table S3, PDF file, 0.1 MB.
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We inferred a phylogenetic tree for all sequences (7,382 sequences collected from 2014 to 2017) using the maximum likelihood (ML) method available in the program RAxML v7.2.6 ([@B47]), incorporating a general time-reversible (GTR) model of nucleotide substitution with gamma-distributed (Γ) rate variation among sites. To assess the robustness of each node, a bootstrap resampling process was performed (500 replicates), again using the ML method available in RAxML v7.2.6. We identified the dominant clades with N162/I216T and S84N sequences that were first detected in 2015 and 2014, respectively, to reconstruct their early evolutionary and dispersal dynamics using a Bayesian approach. For computational efficiency, we removed identical sequences and those shorter than 75% of the 1698 nucleotides of the HA segment, and we separately collected all N162/I216T sequences within the first year of detection (4 January 2015 to 4 January 2016, *n* = 556 sequences) and all S84N sequences within the first year and a half of detection (5 February 2014-02-05 to 22 September 2015, *n* = 291 sequences; [Fig. S6B](#figS6){ref-type="supplementary-material"} and [Fig. S7B](#figS7){ref-type="supplementary-material"}). To obtain a better geographic representation of samples, we subsampled regions with a large number of sequences, taking into account maximum time span and geographic diversity (final N162/I216T data set = 159 sequences; S84N data set = 125 sequences) ([Fig. S6A](#figS6){ref-type="supplementary-material"} and [Fig. S7C](#figS7){ref-type="supplementary-material"}).

Phylogenetic relationships were inferred by the time-scaled Bayesian approach using Markov chain Monte Carlo (MCMC), available via the BEAST v1.8.4 package ([@B48]), and the high-performance computational capabilities of the Biowulf Linux cluster at the National Institutes of Health, Bethesda, MD. A relaxed molecular clock was used, with a Hasegawa-Kishino-Yano 85 (HKY85) model ([@B49]) of nucleotide substitution with gamma-distributed rate variation among sites and either a constant population size or exponential-growth coalescent model. For viruses for which only the year of viral collection was available, the lack of tip date precision was accommodated by sampling uniformly across a 1-year window from January 1st to December 31st. The MCMC tool was run separately at least three times for each of the data sets and for at least 100 million iterations, with subsampling performed every 10,000 iterations, using the BEAGLE library to improve computational performance ([@B50]). All parameters reached convergence, as assessed visually using Tracer v.1.6, with statistical uncertainty reflected in values corresponding to the 95% highest posterior density (HPD). We performed a model comparison analysis by computing the marginal likelihoods of the parametrizations with a constant population size or with the exponential-growth coalescent models, measured by the use of the harmonic mean estimator and the Akaike information criteria through MCMC (AICM). At least 10% of the chain was removed as burn-in, and parallel runs were combined using LogCombiner v1.8.4 and downsampled to generate a final posterior distribution of 500 trees that was used in the subsequent spatial analysis ([@B51]). We found that for both data sets, the exponential-growth model performed better, providing a lower AICM value and positive harmonic mean values that indicate better relative model fit ([Table S3B](#tabS3){ref-type="supplementary-material"}). Results reported above show this parametrization. Nonetheless, the data representing the divergence times are robust, as the highest posterior density intervals largely overlap for both parametrizations ([Fig. S3B](#figS3){ref-type="supplementary-material"}).

The phylogeographic analysis considered 11 and 12 locations for the S84N and N162/I216T data sets, respectively ([Table S3A](#tabS3){ref-type="supplementary-material"}). A nonreversible discrete model was used to infer the rate of location transitions, along with Bayesian stochastic search variable selection (BSSVS) to identify those highly significant transitions while improving statistical efficiency ([@B52]). For computational efficiency, the phylogeographic analysis was run using an empirical distribution of 500 trees ([@B51]), allowing the MCMC chain to be run for 50 million iterations, with sampling every 5,000 iterations. Maximum clade credibility (MCC) trees were summarized using TreeAnnotator v1.8.4, and the trees were visualized in FigTree v1.4.3.

HA homology model. {#s4.6}
------------------

We created a homology model of the influenza A virus HA head domain with Schrödinger\'s Prime module, using the sequence of the Shandong 2009 H1N1 strain (UniProt accession number [F2YI86](https://www.uniprot.org/uniprot/F2YI86)) and the [2WR0](http://www.rcsb.org/pdb/explore/explore.do?structureId=2WR0) structure as a template for the homotrimer assembly. To model the HA stalk, the [2WPQ](http://www.rcsb.org/pdb/explore/explore.do?structureId=2WPQ) structure was identified as a good candidate for trimeric alpha-helical bundles.

Data availability. {#s4.7}
------------------

The reagents and all other raw data are available from J. W. Yewdell upon request. Processed data and sequences supporting this study can be found at <http://downloads.misms.net/Publications/Glycosylation_mBio/index.html>.
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